Autoimmune Beta-Cell Destruction
Type 1 Diabetes Mellitus (T1DM) results from T-cell mediated autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Without insulin, cells cannot utilise glucose and lipolysis produces ketones, risking diabetic ketoacidosis (DKA).
Key mechanism: CD4+ and CD8+ T-lymphocytes infiltrate islets of Langerhans (insulitis). Autoantibodies confirm autoimmunity but are not directly destructive. Destruction can take months to years before clinical presentation.
Diagnostic Autoantibodies
| Antibody | Target | Sensitivity | Notes |
|---|
| GADA Glutamic Acid Decarboxylase | GAD65 enzyme | ~70-80% | Most common; also positive in LADA |
| IA-2A Islet Antigen-2 | Tyrosine phosphatase | ~60-70% | Predicts faster progression |
| ZnT8A Zinc Transporter 8 | Beta-cell zinc transporter | ~60-80% | Useful when GADA/IA-2 negative |
| IAA Insulin Autoantibody | Endogenous insulin | Higher in young onset | Not useful after exogenous insulin started |
C-Peptide Testing
C-peptide is co-secreted with endogenous insulin in equimolar amounts. It distinguishes T1DM from T2DM and guides management.
- T1DM: C-peptide absent or very low (<0.2 nmol/L)
- T2DM: C-peptide normal or elevated
- Test in stimulated state (post-mixed meal or glucagon-stimulated)
- Useful when diagnosis unclear — e.g. lean young adult labelled T2DM
- Low C-peptide + positive antibody = confirmed T1DM/LADA
Nursing note: Urine C-peptide:creatinine ratio (UCPCR) can be used non-fasting — easier for outpatient testing.
LADA — Latent Autoimmune Diabetes of Adults
LADA (Type 1.5 DM) is frequently misdiagnosed as T2DM. Slow autoimmune destruction means it initially responds to oral agents.
- Onset usually age >30 years
- Normal or lean BMI at presentation
- GADA positive (essential diagnostic criterion)
- C-peptide low but detectable initially
- Fails oral therapy within 1-6 years
- Progresses to insulin dependence — often mismanaged for years
Red flag: Adult "T2DM" not responding to metformin/sulphonylurea — check GADA and C-peptide.
HbA1c & Glycaemic Targets
<48 mmol/molMost adults with T1DM
<53 mmol/molFrequent hypoglycaemia risk
<59 mmol/molChildren under 12 years
<48 mmol/molPre-pregnancy (T1DM)
Important: HbA1c is an average and misses glucose variability. Time in Range (TIR) via CGM provides a more complete picture. HbA1c can be falsely low in haemolytic anaemia, haemoglobinopathies (common in GCC populations — sickle cell, thalassaemia).
Time in Range (TIR) Consensus Targets — T1DM Adults
| Zone | Range | Target | Clinical Significance |
|---|
| Time in Range | 3.9–10.0 mmol/L | >70% (>17h/day) | Correlates with HbA1c ~53 mmol/mol |
| Time Above Range (TAR L1) | 10.1–13.9 mmol/L | <25% | Postprandial spikes, HbA1c elevation |
| Time Above Range (TAR L2) | >13.9 mmol/L | <5% | Significant hyperglycaemia risk |
| Time Below Range (TBR L1) | 3.0–3.9 mmol/L | <4% | Level 1 hypoglycaemia |
| Time Below Range (TBR L2) | <3.0 mmol/L | <1% | Severe hypoglycaemia risk zone |
Honeymoon Period
After diagnosis and insulin initiation, remaining beta cells temporarily recover function due to reduced glucose toxicity.
- Duration: weeks to months; rarely up to 2 years
- Insulin requirements fall — risk of hypoglycaemia
- C-peptide detectable during honeymoon
- Patient may erroneously believe diabetes is resolving
- Eventual total beta-cell loss = end of honeymoon
- Education essential: T1DM diagnosis is permanent
Associated Autoimmune Conditions
Annual screening is recommended as T1DM shares autoimmune diathesis with other organ-specific conditions.
- Thyroid disease — Hashimoto's/Graves': annual TSH
- Coeliac disease — TTG-IgA + total IgA at diagnosis & if symptomatic
- Addison's disease — adrenal autoantibodies if unexplained hypoglycaemia or lethargy
- Vitiligo — visual inspection
- Pernicious anaemia — B12, intrinsic factor antibodies if anaemic
GCC note: Thyroid disorders have high prevalence in Gulf female populations — maintain vigilance.
Basal-Bolus Regimen (MDI)
Multiple Daily Injections (MDI) with basal-bolus therapy is the standard of care for T1DM. It mimics physiological insulin secretion: a background (basal) dose controls fasting glucose; rapid-acting (bolus) doses cover meals and corrections.
Principle: ~50% of total daily dose = basal; ~50% = bolus (divided across meals). Adjust based on blood glucose patterns, not single readings.
Insulin Types — Quick Reference
| Insulin | Examples | Onset | Peak | Duration | Administration |
|---|
| Rapid-Acting |
Aspart (NovoRapid), Lispro (Humalog), Glulisine (Apidra) |
10–15 min | 1–2 h | 3–5 h |
Inject with meals or up to 15 min before. Clear solution. |
| Ultra-Rapid |
Faster Aspart (Fiasp), URLi (Lyumjev) |
2–5 min | ~1 h | 3–4 h |
Inject at start of meal or within 20 min of starting. Useful for high-carb meals. |
| Long-Acting Basal |
Glargine (Lantus/Toujeo), Detemir (Levemir), Degludec (Tresiba) |
1–2 h | No peak (flat profile) | 20–42 h |
Once or twice daily at consistent time. Do NOT mix. Clear solution. |
| Pre-Mixed |
NovoMix 30, Humalog Mix25/50 |
Variable | Dual | Variable |
Not recommended for T1DM — fixed ratio limits flexibility. Cloudy. |
Clear vs Cloudy rule: Rapid and long-acting analogue insulins are CLEAR. NPH/pre-mixed insulins are CLOUDY (require gentle rolling — not shaking). Never mix long-acting analogues with other insulins.
Insulin Storage
- Unopened pens/vials: Fridge 2–8°C. Do not freeze. Discard if frozen.
- In-use pen/vial: Room temperature, away from heat/light — up to 28 days (check manufacturer; degludec up to 56 days).
- GCC heat alert: Do not leave in car, near window, or in direct sunlight. Ambient temperatures in GCC often exceed 40°C — insulin degrades rapidly.
- Travel/Hajj: Use insulated insulin wallet (Frio bag — evaporative cooling) — effective in heat without refrigeration.
- Check insulin before injection — discard if cloudy (clear types), clumped, or discoloured.
Injection Technique
- Use 4mm or 6mm needle for most adults — reduces intramuscular injection risk
- 90° angle for most patients; 45° angle + pinch for very lean patients/children (4mm can be given at 90° without pinch in most adults)
- Inject into subcutaneous tissue — not muscle (rapid, unpredictable absorption)
- Hold pen for 10 seconds after injection to prevent leakage
- Site rotation: Abdomen (fastest absorption), thigh (slowest), upper arm, buttock
- Consistent meal-to-injection site improves predictability
- Never reuse needles — blunt tip, lipohypertrophy risk
Lipohypertrophy — Recognition & Prevention
What is it?
Fatty lumps under the skin from repeated insulin injections at same site. Insulin absorption from these sites is erratic — leading to unpredictable glucose control and increased HbA1c.
Up to 50% of T1DM patients have lipohypertrophy — often unrecognised. Palpate injection sites at every clinic visit.
Nursing Assessment
- Visually inspect and palpate all injection sites
- Document location and size on body diagram
- Advise avoidance of affected areas until resolved (months)
- Prescribe structured rotation pattern (grid method)
- Dose may need reducing when rotating away from lipo site — risk of hypoglycaemia
- Never reuse needles
CGM vs Flash Glucose Monitoring
| Feature | CGM (Real-Time) | Flash (FreeStyle Libre) |
|---|
| Real-time readings | Yes — automatic every 1–5 min | On demand — must scan sensor |
| Alarms | Yes — high, low, urgent low, predictive | Libre 2: low alarm only (BT required); Libre 3: real-time |
| Calibration | Dexcom G6/G7: factory calibrated. Guardian 4: factory calibrated. Some older: finger prick required | Factory calibrated |
| Sensor life | 7–14 days depending on device | 14 days (Libre 2); 14 days (Libre 3) |
| Share / remote monitoring | Yes — Dexcom Follow, Guardian Connect | LibreLinkUp app — family/carer viewing |
| Integration with pump | Dexcom G6/G7 + Tandem/Omnipod 5; Guardian 4 + Medtronic 780G | Libre 3 + some pumps |
CGM Devices in GCC
- Dexcom G6/G7 — widely available in UAE, Saudi, Qatar; integrates with Omnipod 5 and Tandem
- FreeStyle Libre 2/3 — most commonly used in GCC due to lower cost; widely available in pharmacy
- Medtronic Guardian 4 — used with Medtronic 780G pump system
- Government health insurance in KSA/UAE increasingly covering CGM for T1DM
- Libre 2 can be scanned through thin clothing — useful for modesty considerations
Sensor Placement & Insertion
- Approved sites: Abdomen (Dexcom), upper arm posterior (Libre) — follow manufacturer guidance
- Avoid waistband area, scar tissue, lipohypertrophy, tattoos
- Ensure skin is clean, dry, alcohol-prepped and fully dried before insertion
- Press firmly for 15–30 seconds after insertion
- Warm-up period: Dexcom G7 = 30 min; Libre 2 = 60 min; Libre 3 = 60 min
- Waterproof: All current CGMs are water-resistant (30 min, 1m depth). Remove for swimming >30 min or use adhesive patches.
CGM Alarms — Nursing Understanding
- Urgent Low Alert: Fixed at 3.1 mmol/L — cannot be turned off (Dexcom G6/G7). Requires immediate treatment.
- Low Alert: User-set, typically 3.9–4.4 mmol/L. Warns before hypoglycaemia.
- Predictive Low: Alerts 15–20 minutes before predicted low based on trend arrow.
- High Alert: User-set, e.g. 10–13.9 mmol/L. Prompts bolus correction or sick day check.
- Signal Loss: Sensor out of range or failed — revert to fingerprick testing.
Trend Arrows:
↑↑ Rising rapidly (>3.3 mmol/L per 5 min) — act urgently
↑ Rising (2–3.3 mmol/L per 5 min)
↗ Rising slowly (1–2 mmol/L per 5 min)
→ Stable
↘ Falling slowly
↓ Falling (2–3.3 mmol/L per 5 min)
↓↓ Falling rapidly — hypoglycaemia imminent
AGP Report Interpretation
The Ambulatory Glucose Profile (AGP) summarises 14+ days of CGM data in a standardised one-page report.
- Median line (50th percentile): Average day pattern
- Interquartile range (25–75th percentile): Narrow = consistent; wide = variable
- TIR/TAR/TBR bands: Colour-coded zones — green (3.9–10), amber (10–13.9), red (>13.9), yellow (3.0–3.9), dark red (<3.0)
- Look for: dawn phenomenon (early AM rise), post-meal spikes, nocturnal hypos
- Use AGP for insulin dose adjustments at clinic
CGM Accuracy Considerations
- Paracetamol (acetaminophen): Can falsely elevate Dexcom G4/G5/Libre 1 readings. Dexcom G6/G7 and Libre 2/3 are not affected.
- Rapid glucose change: CGM measures interstitial fluid — 5–10 min lag behind blood glucose. During rapid falls, CGM reads higher than actual BG — always confirm with fingerprick if symptomatic hypo.
- Compression lows: Lying on sensor causes falsely low readings — reposition, recheck.
- Hospital use: CGM can aid monitoring but should be verified with lab glucose for clinical decisions (DKA, hyperosmolar states).
- CGM in Ramadan: Continuous monitoring is essential — fasting T1DM patients have high DKA and hypoglycaemia risk.
Continuous Subcutaneous Insulin Infusion (CSII) Overview
Insulin pumps deliver continuous rapid-acting insulin subcutaneously, replacing basal-bolus MDI with more precise, programmable delivery. Only rapid-acting insulin is used — NO long-acting insulin with a pump.
Tethered Pumps
- Medtronic MiniMed 780G — SmartGuard closed-loop with Guardian 4 CGM
- Tandem t:slim X2 — Control-IQ closed-loop with Dexcom G6/G7
- Connected via tubing to infusion set and cannula
- Worn on waistband/belt clip/bra/pocket
Tubeless Patch Pump
- Omnipod 5 — automated with Dexcom G6; no tubing
- Omnipod DASH — semi-closed loop (manual bolus)
- Pod worn directly on skin (abdomen, arm, back)
- Controlled via PDM (personal diabetes manager) or smartphone
- Popular in GCC — no tubing, discreet under abaya/thobe
Hybrid Closed-Loop (HCL) Systems
HCL automatically adjusts basal insulin delivery based on real-time CGM readings — reducing hypoglycaemia and improving TIR without requiring constant patient input.
How it works: Algorithm reads CGM every 5 min → increases basal if glucose rising → suspends/reduces if glucose falling → patient still announces meals (bolus wizard) and sets correction targets.
| System | CGM Partner | Algorithm Target | Key Feature |
|---|
| Medtronic 780G + SmartGuard | Guardian 4 | 6.1 mmol/L (fully auto) | Auto correction boluses; automode |
| Tandem t:slim + Control-IQ | Dexcom G6/G7 | 6.25 mmol/L | Sleep mode (tighter overnight control) |
| Omnipod 5 + SmartAdjust | Dexcom G6 | User-set 6.1–8.9 mmol/L | Tubeless; phone-controlled; adjustable target |
Patient education: HCL still requires carbohydrate counting for meal boluses. "Close the loop" means system handles background — not meal insulin. Pre-bolusing before meals improves post-meal TIR.
Bolus Types
- Standard bolus: Full dose delivered immediately — for normal-carb meals
- Square/extended bolus: Dose spread over 1–4 h — for slow-digesting meals (high fat/protein — shawarma, biryani, Arabic mezze)
- Dual-wave bolus: Portion now + remainder over time — high-fat, high-carb meals (e.g. Iftar dates + biryani)
- Correction bolus: (Current BG − Target BG) ÷ ISF — to bring down high glucose
- Always check insulin on board (IOB) before giving correction to avoid stacking
Infusion Set Management
- Change infusion set every 2–3 days (Omnipod pod: every 3 days max)
- Rotate cannula sites — abdomen preferred for fastest, most consistent absorption
- Inspect site at each change — signs of inflammation, infection, tunnelling
- Use aseptic technique for insertion
- Prime tubing fully before connecting to avoid air bubbles
- Disconnecting for >1–2 hours increases DKA risk — T1DM has NO endogenous insulin reserve
Pump Failure & DKA Risk — Critical Nursing Knowledge
URGENT: In T1DM using CSII, any interruption to insulin delivery for >1–2 hours can precipitate DKA within 6–12 hours. Unlike MDI patients, there is NO long-acting insulin on board. Rapid rise in ketones occurs quickly.
Recognising Pump Failure
- Unexplained high blood glucose not responding to pump corrections
- Ketones rising (blood ketones >0.6 mmol/L — act; >1.5 mmol/L — urgent intervention)
- Pump alarm: occlusion alert, empty reservoir, motor error
- Kinked, blocked, or dislodged cannula
- Air bubbles in tubing (tethered pumps)
Action if Pump Failure Suspected
- Check blood glucose AND blood ketones immediately
- Change infusion set, cannula, and reservoir — use fresh site
- If DKA developing: give correction dose via pen injection (not pump until cause identified)
- Contact diabetes team if ketones >1.5 mmol/L or glucose not falling after set change
- All pump patients must have MDI pen insulin available as backup at all times
Sick Day Rules — Insulin Pump
- Do NOT stop insulin pump during illness — insulin needs increase with infection/stress
- Check blood glucose every 2–4 hours
- Check blood ketones every 2–4 hours if glucose >14 mmol/L
- Increase basal rate by 20–50% depending on illness severity (follow personalised sick-day plan)
- Give correction boluses via pump or pen every 2–4 h if ketones rising
- Maintain fluid intake — at least 100–200 mL/h if able
- If vomiting, unable to keep fluids down, or ketones >3.0 mmol/L — emergency hospital attendance
Hypoglycaemia Classification
3.0–3.9Level 1 — Alert
<3.0Level 2 — Significant
Any BGLevel 3 — Severe
Level 3: Cognitive impairment requiring third-party assistance — regardless of blood glucose value. Includes seizure, loss of consciousness, inability to self-treat.
Treatment Algorithm — Conscious Patient
Level 1: BG 3.0–3.9 mmol/L
15-15 Rule:
Give 15g fast-acting carbohydrates.
Recheck BG after 15 minutes.
If still <4.0, repeat 15g CHO.
Once BG >4.0: have a snack if next meal >1h away.
150–200 mL fruit juice
150 mL regular (non-diet) cola
4–5 glucose tablets
3–4 tsp glucose powder in water
GlucoGel tube (40% glucose)
Level 2: BG <3.0 mmol/L
20g fast-acting CHO immediately.
Recheck in 15 minutes.
If still <3.9: give further 15g CHO.
Identify and address cause.
Do NOT give bolus insulin until BG stable >5.0.
200–250 mL fruit juice
5–6 glucose tablets
200 mL cola (non-diet)
Level 3 — Severe Hypoglycaemia Treatment
Patient is unconscious, seizure, or unable to swallow — do NOT give anything by mouth.
| Treatment | Dose & Route | Notes |
|---|
| Glucagon — Nasal (Baqsimi) | 3mg intranasal — one puff in one nostril | No IV access needed. Can be given by carer/family. Works even if unconscious. Repeat after 15 min if no response. |
| Glucagon — IM Kit | 1mg IM (0.5mg if <25 kg child) | Reconstitute from kit. Can be given by trained carer. Takes 10–15 min to act. Side effect: nausea/vomiting. |
| IV Glucose (hospital) | 150 mL of 10% glucose IV over 15 min | First-line in hospital. Recheck BG at 15 min. If no IV access: use Glucagon IM or nasal. Avoid 50% dextrose — vein damage. |
Post-severe hypoglycaemia: Once conscious and able to swallow — give 20–40g complex carbohydrate (bread/crackers). Identify precipitating cause. Review insulin doses. Do NOT resume insulin until BG >5.0 and patient stable.
Hypoglycaemia Unawareness
Impaired Awareness of Hypoglycaemia (IAH) occurs when the adrenergic warning symptoms are blunted — usually from recurrent hypoglycaemia. Gold standard detection: Gold/Clarke score.
- Risk increases with T1DM duration, strict glycaemic control, renal impairment
- Normal warning symptoms (sweating, trembling, palpitations) absent
- Patient may become cognitively impaired without warning
- Management: Relax HbA1c target temporarily; raise CGM alarm thresholds to 5.0–5.5 mmol/L
- Structured education: DAFNE (Dose Adjustment For Normal Eating) or BERTIE programme — evidence base for restoring awareness
- Avoidance of hypoglycaemia for 2–3 weeks can restore counter-regulatory response
- CGM or pump with suspend-before-low essential
Nocturnal Hypoglycaemia
- Common in T1DM — often undetected without CGM
- Risk factors: alcohol evening, exercise day before, excessive evening correction dose
- Signs (retrospective): morning headache, night sweats, unrefreshing sleep, unexplained high morning BG (Somogyi effect — reactive hyperglycaemia post-nocturnal hypo)
- CGM overnight alarm at 4.5–5.0 mmol/L is essential in high-risk patients
- Pump suspend-on-low / HCL algorithms reduce nocturnal hypoglycaemia significantly
- Bedtime snack (complex carb + protein) if BG <7.0 at bedtime
- Consider reducing evening basal or long-acting insulin
Inpatient Hypoglycaemia — Hospital Protocol Summary
- BG <4.0 mmol/L — treat even if asymptomatic (inpatients may not feel symptoms due to illness)
- Conscious, able to swallow: 150–200 mL fruit juice or 4–5 glucose tablets; recheck 15 min
- Unconscious/NBM/swallowing impaired: 150 mL 10% IV glucose over 15 min; recheck 15 min
- Repeat treatment if BG still <4.0 at 15 min recheck
- After recovery: identify cause (missed meal, excessive insulin dose, change in renal function, NPO status not communicated to prescriber)
- Document incident — complete incident report for BG <3.0 mmol/L
- Review insulin prescriptions — do not resume full dose until cause identified and addressed
- Escalate to diabetes specialist team if recurrent inpatient hypoglycaemia
T1DM Epidemiology in the GCC
The GCC has one of the highest incidences of childhood T1DM globally, with Saudi Arabia among the top 10 countries worldwide for T1DM incidence. Contributing factors are multifactorial.
Risk Factors in GCC Populations
- Consanguinity: High rates of first-cousin marriage in some GCC communities increase autoimmune genetic risk (HLA-DR3/DR4 predisposition)
- Vitamin D deficiency: Despite abundant sunshine — sun avoidance, covered dress, indoor lifestyle. VitD plays an immunomodulatory role.
- Viral triggers: Enteroviral infections (Coxsackie B) — common in young children
- Rapid lifestyle changes: Westernisation, urban diet changes, hygiene hypothesis
- Rising obesity: T2DM co-existing with T1DM features (double diabetes) increasingly reported
Saudi Arabia T1DM Data:
Incidence: ~33 per 100,000 children per year (KSA) — one of highest globally.
UAE: T1DM prevalence 0.3–0.5% of population; increasing in expatriate paediatric community.
Kuwait/Qatar/Oman/Bahrain: Similarly elevated paediatric T1DM incidence with ongoing national registry development.
Ramadan Fasting & T1DM
Important: T1DM patients are classified as HIGH RISK for Ramadan fasting by EPIDIAR (Epidemiology of Diabetes and Ramadan) and IDF. Islamic scholars confirm exemption from fasting for those with serious illness — this includes most T1DM patients. Nurses must educate respectfully without forcing decisions.
If the Patient with T1DM Chooses to Fast
| Time | Consideration | Action |
|---|
| Pre-Ramadan (1–2 months before) | Risk assessment and education | HbA1c, CGM review, structured education session, personalised Ramadan insulin plan |
| Suhoor (pre-dawn meal) | Last meal — long fast ahead | Reduce rapid-acting insulin by 20–30% for Suhoor. Complex carbs preferred (oats, lentils). Do NOT take correction bolus that might cause daytime hypo. |
| During fast (daytime) | No food or drink 14–18h | Reduce basal rate (pump: reduce by 20–30%). CGM essential — check trend arrows. Break fast if BG <5.5 mmol/L, <3.9 mmol/L (mandatory), or >16.7 mmol/L with ketones. |
| Iftar (fast-breaking) | Large meal — typically dates + water + full meal | Give mealtime bolus at Iftar. Dual-wave bolus for high-fat Iftar meal. Monitor 2h post-Iftar for hyperglycaemia. Dates = rapid CHO (1 date ≈ 6–7g CHO). |
| Tarawih prayers (evening) | 1–2h of standing/walking prayer | Anticipate exercise-related glucose drop. Reduce evening correction dose. CGM alarms active. |
Break the fast immediately if: BG <3.9 mmol/L at any time | BG <5.5 mmol/L in first few hours of fast | BG >16.7 mmol/L | Blood ketones >0.6 mmol/L | Symptoms of severe hypo or DKA.
Hajj & T1DM
Hajj involves up to 10–20 km of walking daily, extreme heat (40–45°C), disrupted sleep, and altered meal times — all posing significant diabetes management challenges.
- Insulin storage in heat: FRIO cooling wallets essential. Do not leave insulin in tent in direct sun. Carry spare pens/pump supplies.
- Exercise effect: Extended walking significantly lowers BG — anticipate and reduce basal by 20–40%. Check BG before major walking phases.
- Pump vs MDI: Pump with CGM preferred — allows temporary basal reduction. MDI patients need pre-planned reduction in basal dose.
- Dehydration: Heat + dehydration concentrate blood glucose — monitor closely. Adequate fluid intake (water — permitted during Hajj activities).
- CGM: Sensor adhesion may be reduced due to sweating — use over-patches. Check CGM calibration in heat.
- Register with official Hajj medical services on arrival. Carry medical ID in Arabic & English.
Insulin Access & Cost in GCC
- Government hospitals (KSA/UAE/Qatar/Kuwait): Insulin and CGM largely provided free for citizens with T1DM
- Expatriate workers: Dependent on employer health insurance — coverage varies. Some schemes exclude pre-existing conditions.
- CGM cost: Libre sensors ~USD $50–70 per sensor (14 days) in GCC private sector. Dexcom higher cost. Government programs in KSA increasingly subsidising CGM.
- Insulin analogues vs human insulin: Analogue insulins (aspart, glargine) widely available in GCC — prefer over human insulin for T1DM
- Pump consumables: Infusion sets and pods require continuous supply — important for pump patients travelling or on limited income
School Management of T1DM Child in GCC
- School nurse training essential — most GCC schools now required to have health staff
- Individual Diabetes Management Plan (IDMP) — signed by parents, endocrinologist, and school health staff
- Teachers should be aware of hypoglycaemia symptoms and first aid (NOT full treatment — school nurse responsibility)
- Glucose tablets/juice stored in classroom AND nurse office — must be accessible immediately
- CGM alarms must be permitted to be active during class
- Physical education: reduced insulin before PE; glucose snack beforehand
GCC School Context:
Saudi Ministry of Education issued guidelines for management of chronic diseases in schools (2019). UAE schools require annual medical clearance and school health forms for children with T1DM. In Kuwait and Qatar, dedicated school health nurses assist with insulin administration and CGM interpretation during the school day.
Culturally Appropriate Carbohydrate Education — Arabic Food Context
Carbohydrate counting must be taught using familiar GCC foods. Generic Western food lists are ineffective. Nurses should use culturally validated Arabic dietary resources.
| Food | Portion | Approx CHO (g) | Notes |
|---|
| White rice (cooked) | 1 cup (180g) | ~45g | High GI — rapid BG spike. Basmati slightly lower GI. |
| Khubz (Arabic flatbread) | 1 medium piece (~80g) | ~40g | Very common at all meals. Whole wheat available — lower GI. |
| Dates (fresh Medjool) | 1 date (~24g) | ~18g | Very high GI — rapid acting. Common at Iftar. 3 dates = ~54g CHO. |
| Dates (dried, Deglet) | 1 date (~7g) | ~5.5g | Concentrated sugar. Easy to over-consume. |
| Harees (wheat+meat porridge) | 1 bowl (~300g) | ~50–60g | Ramadan staple. Slow-release CHO from whole wheat. |
| Orange juice (fresh) | 1 glass (200mL) | ~20g | Useful for hypo treatment. Fast-acting. |
| Watermelon | 1 slice (~300g) | ~20g | High GI. Common in GCC summer. |
| Mango | 1 medium (~200g) | ~25–30g | Popular in GCC — significant CHO content. |
| Lentil soup | 1 bowl (~300mL) | ~25g | Lower GI due to protein/fibre. Good meal choice. |
| Kunafa (dessert) | 1 slice (~150g) | ~50–60g | High sugar + fat. Significant post-meal spike. Extended bolus useful. |
Insulin Dose Calculator
Mealtime bolus & correction dose estimator — educational use only. Always verify with your diabetes team.
Carbohydrate Bolus (CHO ÷ ICR)
—
Correction Dose ((BG − Target) ÷ ISF)
—
Total Mealtime Dose
—
High Dose Warning: Calculated dose exceeds 20 units. Please double-check carbohydrate count, ICR, and ISF values with your diabetes team before administering.
Correction Only: Blood glucose is below 7.0 mmol/L with no food planned. A carbohydrate bolus is not required — correction dose only (if applicable). Verify no insulin on board (IOB) from previous doses.
Hypoglycaemia Alert: Current blood glucose is below 4.0 mmol/L. Do NOT give insulin. Treat hypoglycaemia first with fast-acting carbohydrates, recheck in 15 minutes, and reassess once BG >5.0 mmol/L.
Note: Blood glucose is already at or below target — no correction dose needed. Carbohydrate bolus only (for food).
Hypoglycaemia Treatment Guide
Level 1 (3.0–3.9 mmol/L) — 15g CHO options:
150mL fruit juice
4–5 glucose tablets
150mL regular cola
1 GlucoGel tube
3 tsp glucose powder
Level 2 (<3.0 mmol/L) — 20g CHO options:
200mL fruit juice
5–6 glucose tablets
200mL regular cola
4 tsp glucose powder
Level 3 (Severe — unconscious/seizure): Glucagon nasal (Baqsimi 3mg) OR Glucagon IM 1mg OR IV 10% glucose 150mL over 15 min. Do NOT give anything orally. Call for help immediately.